Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Fitzgerald

Neonatal-Perinatal Medicine Aurora, CO Medical Doctor

NPI 1477640266 CMS profile 1278727

13123 E 16Th Ave, Aurora, CO 80045

Open in the dashboard

General payments

$192,487

341 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Fitzgerald of Aurora, CO is reported in the CMS Open Payments database as having received $192,487 across 341 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Neonatal-Perinatal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $34,278 61
2024 General $38,236 68
2023 General $37,982 85
2022 General $41,786 71
2021 General $2,760 2
2020 General $12,315 12
2019 General $25,129 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Fitzgerald
  • Neonatal-Perinatal Medicine median
  • Middle half of Neonatal-Perinatal Medicine
  • National median

In program year 2025, general payments to Michael Fitzgerald were reported at $34,278. Among 879 Neonatal-Perinatal Medicine profiles paid that year, the median was $77 and the middle half received between $26 and $145.

Show as a table
Year Michael Fitzgerald Neonatal-Perinatal Medicine median Middle half National median
2019 $25,129 $70 $22–$125 $163
2020 $12,315 $39 $18–$108 $114
2021 $2,760 $49 $18–$122 $132
2022 $41,786 $47 $21–$149 $149
2023 $37,982 $49 $23–$140 $160
2024 $38,236 $65 $24–$132 $164
2025 $34,278 $77 $26–$145 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Fresenius Kabi USA, LLC $192,287 335 payments
  2. Chiesi USA, Inc. $110 2 payments
  3. Janssen Pharmaceuticals, Inc $45 2 payments
  4. Sobi, Inc $26 1 payment
  5. AstraZeneca Pharmaceuticals LP $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $87,120 41 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $56,850 23 payments
  3. Travel and Lodging $43,113 221 payments
  4. Food and Beverage $5,404 56 payments
Products named General payments · program years 2019–2025
  1. Smoflipid $152,082 279 payments
  2. PH-Omegaven $25,129 42 payments
  3. OMEGAVEN $2,760 2 payments
  4. CUROSURF $110 2 payments
  5. SPRAVATO $45 2 payments
  6. SYNAGIS $26 1 payment
  7. FASENRA $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

341 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neonatal-Perinatal Medicine in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record